Today Stories

BURLINGTON, N.C. (January 29, 2025) – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's 2025 list of the World’s Most Admired Companies,™ a recognition of the most respected and reputable companies globally. “We are proud to once again be named to FORTUNE’s World's Most Admired Companies list,” said Adam Schechter, chairman and CEO of Labcorp. “This honor reflects the continuous hard work and commitment of our employees to help us advance our mission to improve health and improve lives around the world.”   Labcorp ranked second in the “Healthcare: Pharmacy and Other Services” category, up from fourth place in 2024, scoring top marks in quality of management, financial soundness, long-term investment and…

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the enlarged Corporate Executive Committee starting 10 February 2025.  She will be based at Genentech in South San Francisco. In this new role, she will take over the worldwide responsibility for the Informatics function for the Roche Group from Alan Hippe, who currently has the dual role of Chief Financial Officer (CFO) and Chief Informatics Officer (CIO).  With our ambitions to transform our business with digital solutions and through enterprise-wide use of artificial intelligence, this is the right moment to split the two roles and ensure dedicated foc…

New next generation sequencing-based proteomics kits designed to integrate with multiple NGS platforms, eliminating the need for new instrumentation or specialized expertise UPPSALA, Sweden--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the introduction of Olink® Reveal, setting a new standard for affordable, high-plex proteomics that enables researchers to identify circulating biomarkers for a range of applications with reduced cost and set up requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250126428090/en/ New Olink Reveal next generation sequencing-based proteomics kits are designed to integrate with multiple NGS platforms, eliminating the need for new instrumen…

Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology GSK to invest up to £50 million in collaboration to generate key insights on how cancer develops that could inform future development of cancer vaccines Programme adds to existing relationship, including the ongoing GSK-Oxford Institute of Molecular and Computational Medicine GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform new…

Researchers at Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden have determined how children’s immune systems react to different kinds of cancer depending on their age. The study, which is published in the journal Cell, reveals significant differences between the immune response of children and adults, and has the potential to lead to new tailored treatments for children with cancer. “The activation of the immune system is crucial to our ability to fight cancer, but differs between children and adults,” says Petter Brodin, professor of paediatric immunology at the Department of Women’s and Children’s Health, Karolinska Institutet, and paediatrician at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital. “If we’re to properly treat childhood ca…

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone. AUTs evaluate the use of the medicine under real-world conditions to identify any issues that have not previously been identified and to confirm that consumers can self-diagnose and treat themselves appropriately without the help of a healthcare provider. Julie Van OngevallePresident and CEO, Opella“We are pleased that the FDA has completed the…

The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be addressed to increase public acceptance of breakthrough innovations / More than 13,000 people surveyed in 13 countries representing every continent except Antarctica / The survey explored the public’s perceptions of cell and gene therapies, AI in medicine, new genomic techniques (NGTs) in agriculture, and cultivated meat Berlin, Germany, January 20, 2025 – As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was con…

German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors. Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Inst…

RESEARCH TRIANGLE PARK, N.C. – January 13, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.  The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA and NVIDIA will help accelerate IQVIA Healthcare-grade AI™, enabling new levels of agentic automation of complex and time-consuming workflows across the therapeutic life cycle with the precision, scalability, and trust required by IQVIA’s customers. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered…

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers GSK to pay up to $1.15 billion GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based reg…

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are having a profound impact on our customers’ fundamental understanding of disease and the advancement of life sciences research,” said Marc N. C…

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease Expanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6 billion dollars, plus R&D funding and potential royalty payments Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (…

Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα expressing cancers.  For the first time, the cross-functional teams were able to scale up Sutro’s cell-free protein synthesis platform from a small-scale Good Manufacturing Practice (GMP) production to a large-scale GMP production marking an industry milestone. All batches of luvelta manufactured in 4,500 L at Boehringer’s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for the…

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari’s innovative product portfolio is highly complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Each year, VTE impacts u…

Waves of human migration across Europe during the first millennium AD have been revealed using a more precise method of analysing ancestry with ancient DNA, in research led by the Francis Crick Institute. Researchers can bring together a picture of how people moved across the world by looking at changes in their DNA, but this becomes a lot harder when historical groups of people are genetically very similar.  In research published today in Nature, researchers report a new data analysis method called Twigstats1, which allows the differences between genetically similar groups to be measured more precisely, revealing previously unknown details of migrations in Europe. They applied the new method to over 1500 European genomes (a person’s complete set of DNA) from people who lived primarily dur…

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi Strengthens its leadership team with the appointments of industry veterans Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution IND-enabling studies underway for first-in-class PD1/VEGFR2 bifunctional antibody [19 December 2024]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for mul…

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US). The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here. “We are very pleased with the completion of the acquisition. The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant internal supply chain expansions. The acquisition will enable us to reach significantly more people living with serious chronic dise…

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies to revolutionize care for people with slow or irregular heart rhythms ABBOTT PARK, Ill., Dec. 17, 2024 ­­­/PRNewswire/ -- Abbott (NYSE: ABT) today announced the successful completion of the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational AVEIR™…

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within…

Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.   The new site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future.    "The facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” says Henrik Wulff, executive vice p…